Sector revisions Neurogene Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
17.38 ^USD	+2.24%		+0.87%	-15.63%

02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. Revenue rev.	1y. Revenue rev.	Visibility	Nbr of analysts
NEUROGENE INC.	-	-	-	-	5
LONZA GROUP AG				-	23
BEONE MEDICINES AG				-	24
CELLTRION, INC.				-	23
IQVIA HOLDINGS INC.				-	20
REVOLUTION MEDICINES, INC.				-	18
EUROFINS SCIENTIFIC SE				-	15
ASCENDIS PHARMA A/S				-	16
IONIS PHARMACEUTICALS, INC.				-	22
MEDPACE HOLDINGS, INC.				-	12
QIAGEN N.V.				-	15
ABIVAX				-	5
BIO-TECHNE CORPORATION				-	12
TEMPUS AI, INC.				-	12
PRAXIS PRECISION MEDICINES, INC.				-	16
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.				-	15
PHARMARON BEIJING CO., LTD.				-	13
HANGZHOU TIGERMED CONSULTING CO., LTD				-	11
ICON PUBLIC LIMITED COMPANY				-	15
Average					15
Weighted average by Cap.					19